Cystic Fibrosis

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

By

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

By

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Five things for pharma marketers to know: Thursday, January 28, 2016

Five things for pharma marketers to know: Thursday, January 28, 2016

By

Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

By

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.